| Correction to: Hepatocellular carcinoma (Nature Reviews Disease Primers,(2021), 7, 1,(6), 10.1038/s41572-020-00240-3) JM Llovet, RK Kelley, A Villanueva, AG Singal, E Pikarsky, S Roayaie, ... Nature Reviews Disease Primers 10 (1), 10, 2024 | 2 | 2024 |
| TOP-507-YI Single-cell RNA sequencing-derived gene signatures reveal distinct response mechanisms to atezolizumab+ bevacizumab in advanced hepatocellular carcinoma S Cappuyns, M Piqué-Gili, R Esteban-Fabró, G Philips, R Pinyol, ... Journal of Hepatology 80, S411-S412, 2024 | | 2024 |
| FRI-467 Efficacy of WNTinib, a novel selective therapeutic for CTNNB1 mutant tumors, in preclinical models of hepatoblastoma U Balaseviciute, J Abril-Fornaguera, J Huguet-Pradell, A Rialdi, ... Journal of Hepatology 80, S417-S418, 2024 | | 2024 |
| REPLACE: A phase III, randomized, open-label trial to evaluate the safety and efficacy of regorafenib and pembrolizumab versus locoregional therapy (LRT) with transarterial … PR Galle, M Kudo, JM Llovet, AL Cheng, R Lencioni, Y Oviedo, K Desai, ... Journal of Clinical Oncology 42 (16_suppl), TPS4200-TPS4200, 2024 | | 2024 |
| Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma JM Llovet, R Pinyol, M Yarchoan, AG Singal, TU Marron, M Schwartz, ... Nature Reviews Clinical Oncology 21 (4), 294-311, 2024 | 13 | 2024 |
| HIMALAYA Overall Survival Prominence and Other Routes to the Peak—Reply JM Llovet, S Cappuyns, RS Finn JAMA oncology 10 (3), 1-1, 2024 | | 2024 |
| Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy CJ O'Rourke, M Salati, C Rae, G Carpino, H Leslie, A Pea, MG Prete, ... Gut 73 (3), 496-508, 2024 | 7 | 2024 |
| Hepatocellular carcinoma (vol 7, 6, 2021) JM Llovet, RK Kelley, A Villanueva, AG Singal, E Pikarsky, S Roayaie, ... NATURE REVIEWS DISEASE PRIMERS 10 (1), 2024 | | 2024 |
| Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors YL Wu, S Cappuyns, A Loh, S Sun, S Lewis, MW Sung, M Schwartz, ... BJC Reports 2 (1), 8, 2024 | 2 | 2024 |
| Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma … L Rimassa, D Li, M Ikeda, M Yarchoan, BY Ryoo, T Kossler, HY Lim, ... Journal of Clinical Oncology 42 (3_suppl), 484-484, 2024 | | 2024 |
| Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP … RS Finn, M Kudo, P Merle, T Meyer, S Qin, M Ikeda, R Xu, J Edeline, ... Journal of Clinical Oncology 42 (3_suppl), 482-482, 2024 | | 2024 |
| Epidermal Growth Factor Receptor Inhibition With Erlotinib in Liver: Dose De-Escalation Pilot Trial as an Initial Step in a Chemoprevention Strategy KK Tanabe, D Zahrieh, CA Strand, Y Hoshida, TJ Flotte, G Della’Zanna, ... Gastro Hep Advances 3 (3), 426-439, 2024 | | 2024 |
| AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (May, 10.1097/HEP. 0000000000000466, 2023) AG Singal, JM Llovet, M Yarchoan, N Mehta, JK Heimbach, LA Dawson Hepatology 78 (6), E105-E105, 2023 | 1 | 2023 |
| Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial JM Llovet, M Kudo, P Merle, T Meyer, S Qin, M Ikeda, R Xu, J Edeline, ... The Lancet Oncology 24 (12), 1399-1410, 2023 | 79 | 2023 |
| Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy AG Singal, F Kanwal, JM Llovet Nature reviews Clinical oncology 20 (12), 864-884, 2023 | 85 | 2023 |
| AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma AG Singal, JM Llovet, M Yarchoan, N Mehta, JK Heimbach, LA Dawson, ... Hepatology 78 (6), 1922-1965, 2023 | 364 | 2023 |
| A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116 M Kudo, RS Finn, M Ikeda, MW Sung, AD Baron, T Okusaka, M Kobayashi, ... Liver Cancer, 2023 | | 2023 |
| Atezolizumab Plus Bevacizumab in Advanced HCC: Efficacy in NASH-Specific Etiology JM Llovet, M Heikenwalder Gastroenterology 165 (5), 1308-1310, 2023 | 2 | 2023 |
| HUMAN-CORRELATED GENETIC HCC MODELS IDENTIFY COMBINATION THERAPY FOR PRECISION MEDICINE M Mueller, S May, H Hall, TJ Kendall, L McGarry, L Blukacz, S Nuciforo, ... HEPATOLOGY 78, S101-S101, 2023 | | 2023 |
| PREDICTING RESPONSE TO ATEZOLIZUMAB PLUS BEVACIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA S Cappuyns, M Pique-Gili, R Esteban-Fabro, G Philips, R Pinyol, ... Hepatology 78, S1871-S1872, 2023 | | 2023 |